Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Obecabtagene autoleucel · 3 trials · 3 indications
CRR is defined as change in * urine protein creatinine ratio (UPCR) and * estimated glomerular filtration rate (eGFR) and * without use of rescue medication
Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs
| Arm | Type | Description |
|---|---|---|
| Obe-cel | EXPERIMENTAL | - |
| Obecabtagene autoleucel (obe-cel) | EXPERIMENTAL | - |
| AUTO1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obecabtagene autoleucel | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion |
| Obecabtagene autoleucel (obe-cel) | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion. |
Inclusion Criteria: * Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative * Ability and willingness to adhere to protocol's Schedule of Activities and other requirements * Participants must be 12 t...